Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07526116RecruitingPhase 1
Safety study of REGN22044 in healthy adults
This is an early-stage safety study testing a new experimental drug called REGN22044 in people with no serious health conditions. Researchers want to understand how safe the drug is, how well people tolerate it, and how the body processes it.
Ghent, Oost-VlaanderenAges 18–65 - NCT07525960RecruitingPhase 1
Testing NDI-5001 for X-linked Nephrogenic Diabetes Insipidus
This study tests a new drug called NDI-5001 in adult men with a specific genetic form of nephrogenic diabetes insipidus (a condition where the kidneys cannot concentrate urine properly). The trial checks whether the drug is safe, how your body handles it, and whether it might help reduce excessive urination and thirst.
Jacksonville, FloridaAges 18–55 - NCT07531316RecruitingPhase 1
Safety study of VVZ-2471 in healthy volunteers with high impulsivity
This Phase 1 study tests how safe and well-tolerated a new experimental drug called VVZ-2471 is in healthy adults. The drug targets brain pathways involved in impulse control, and researchers want to understand its effects on people who naturally tend to act without thinking.
Richmond, VirginiaAges 18–65 - NCT07521345RecruitingPhase 1
Safety Study of HSK55879 Tablet in Healthy Adults
This early-stage study tests how a new experimental medication (HSK55879) is tolerated and processed by the body in healthy volunteers. Researchers will also check how food affects the drug's absorption to help determine safe dosing for future patient studies.
Hefei, AnhuiAges 18–45 - NCT07521046RecruitingPhase 1
Adding interferon to ruxolitinib for myelofibrosis
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
Salt Lake City, UtahAges 18 years+ - NCT07516405RecruitingPhase 1
Psilocybin Safety Study in Older Adults
This research tests whether psilocybin (a psychoactive compound from certain mushrooms) is safe and well-tolerated in healthy people aged 65–85. Researchers want to understand how older adults respond to this substance and whether it could be useful for future treatments.
San Francisco, CaliforniaAges 65–85 - NCT07522970RecruitingPhase 1
Safety and Tolerability Study of LG-0317 in Healthy Adults
This early-stage study tests a new experimental drug called LG-0317 in healthy volunteers to see if it is safe and how the body processes it. If you are healthy and meet the basic requirements, this trial may help advance a new treatment option.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07511205RecruitingPhase 1
Study of AZD1043 for overweight or obesity
This trial tests a new medicine called AZD1043 in healthy adults who are overweight or have obesity. It aims to see if the medicine is safe and how the body handles it.
Glendale, CaliforniaAges 18–65 - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07510061Recruiting
How your body handles mild heat
This study looks at how your body responds to mild heat depending on where you live and your specific traits. If you are a healthy adult in Denmark or Greece, you may be able to help researchers understand differences in heat resilience.
CopenhagenAges 18–65 - NCT07500506RecruitingPhase 3
Safety of a fifth dose of the Lyme disease vaccine
This study is for people who have already received four doses of the Lyme vaccine (VLA15) in a previous study. It tests whether a fifth dose is safe and helps the body build more protection against Lyme disease.
Bangor, MaineAges 7 years+ - NCT07501455Recruiting
Studying toothpaste and mouth rinse effects on gum inflammation
This study tests whether using a certain toothpaste and mouth rinse can reduce gum inflammation (gingivitis) better than brushing alone. It is for people with mild to moderate gum disease who have not used tobacco or certain medications recently.
Somerville, MassachusettsAges 18–60 - NCT07498725RecruitingPhase 1/Phase 2
Study of LRK-4189 for solid tumors that have spread or can't be removed
This trial tests a new drug called LRK-4189, alone or with other treatments, for people with advanced solid tumors that have worsened despite prior therapy. The goal is to see if it is safe, tolerable, and helpful against the cancer.
NiceAges 18 years+ - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT07500181RecruitingPhase 1
Testing the safety of a new antibiotic in healthy adults
This trial tests an investigational antibiotic called BAL2420 to see if it is safe and how the body processes it. Healthy volunteers are needed to help determine the right dose before it can be studied in people with infections.
GroningenAges 18–55 - NCT06556394RecruitingPhase 1
Testing RAG-17 for ALS with SOD1 gene mutation
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
BeijingAges 18 years+ - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07490951Recruiting
CAR-T cell therapy for refractory autoimmune diseases
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Wuhan, HubeiAges 18–70 - NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT07494045RecruitingPhase 2
Study of CTAP101 for kids with chronic kidney disease
This study tests a new extended-release capsule (CTAP101) for children aged 8 to under 18 with moderate to severe chronic kidney disease (CKD). The goal is to see how the drug works in the body, if it's safe, and if it can help control mineral and hormone levels that are often out of balance in CKD.
Kansas City, MissouriAges 1 month–17 years - NCT07491172RecruitingPhase 1
Trial of CTX310 for stubborn high cholesterol and fats
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
Hialeah, FloridaAges 18–75 - NCT07484204RecruitingPhase 1
Study of a once-monthly injection for stable schizophrenia
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
AhmedabadAges 18–65 - NCT07486115RecruitingPhase 1
Testing safety of BI 3814916 in healthy volunteers
This trial tests how safe and tolerable different doses of the study drug BI 3814916 are in healthy adults. It helps find the right dose for future studies.
EdegemAges 18–65 - NCT07483827RecruitingPhase 1
Testing CPV-104 safety in healthy people and C3G patients
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
ViennaAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.